Walleye Capital LLC Sells 290,994 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA)

Walleye Capital LLC cut its holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) by 72.4% during the 4th quarter, Holdings Channel reports. The firm owned 110,988 shares of the company’s stock after selling 290,994 shares during the period. Walleye Capital LLC’s holdings in Cabaletta Bio were worth $252,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. LPL Financial LLC lifted its holdings in Cabaletta Bio by 15.6% in the 4th quarter. LPL Financial LLC now owns 42,386 shares of the company’s stock worth $96,000 after buying an additional 5,716 shares during the period. Intech Investment Management LLC raised its stake in Cabaletta Bio by 42.2% in the fourth quarter. Intech Investment Management LLC now owns 20,203 shares of the company’s stock worth $46,000 after buying an additional 5,999 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Cabaletta Bio by 23.3% in the fourth quarter. SG Americas Securities LLC now owns 43,259 shares of the company’s stock worth $98,000 after buying an additional 8,161 shares during the period. Barclays PLC boosted its position in Cabaletta Bio by 17.2% during the 4th quarter. Barclays PLC now owns 71,617 shares of the company’s stock valued at $163,000 after acquiring an additional 10,487 shares in the last quarter. Finally, Miller Financial Services LLC bought a new stake in Cabaletta Bio during the 4th quarter valued at approximately $33,000.

Cabaletta Bio Price Performance

Shares of CABA opened at $1.27 on Friday. Cabaletta Bio, Inc. has a twelve month low of $0.99 and a twelve month high of $13.50. The company has a market capitalization of $64.44 million, a P/E ratio of -0.59 and a beta of 2.44. The firm has a 50 day moving average of $1.53 and a 200 day moving average of $2.52.

Cabaletta Bio (NASDAQ:CABA) last posted its earnings results on Monday, March 31st. The company reported ($0.65) EPS for the quarter, hitting analysts’ consensus estimates of ($0.65). On average, sell-side analysts expect that Cabaletta Bio, Inc. will post -2.34 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on CABA shares. UBS Group lowered their target price on Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Guggenheim restated a “buy” rating and set a $23.00 target price on shares of Cabaletta Bio in a report on Tuesday, April 1st. Wells Fargo & Company decreased their price target on shares of Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 1st. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Cabaletta Bio in a research note on Tuesday, April 1st. Finally, Morgan Stanley decreased their target price on shares of Cabaletta Bio from $30.00 to $22.00 and set an “overweight” rating for the company in a research note on Tuesday, April 1st. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $21.00.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.